Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces NMPA Granted Marketing Approval for SULINNO\u00ae (Adalimumab Injection) in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Innovent Biologics"},{"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent\u2019s Product SULINNO\u2019s New Indication Approved by NMPA China, For Patients with Polyarticular Juvenile Idiopathic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Innovent Biologics"},{"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius Adalimumab Biosimilar Approved by NMPA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Shanghai Henlius Biotech"}]

Shanghai Henlius Biotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Henlius Adalimumab Biosimilar Approved by NMPA

Details:

Adalimumab is the third monoclonal antibody developed by Henlius and approved in China, after the Company's rituximab biosimilar HLX01, and trastuzumab biosimilar HLX02, the first China-developed mAb biosimilar approved both in China and in the EU.

Lead Product(s): Adalimumab

Therapeutic Area: Immunology Product Name: HLX03

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 07, 2020

ASK
US

Upload
your Pipeline Activity

Innovent Biologics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Innovent’s Product SULINNO’s New Indication Approved by NMPA China, For Patients with Polyarticular Juvenile Idiopathic Arthritis

Details:

SULINNO® (adalimumab injection) is a recombinant human anti-TNF-α monoclonal antibody drug approved by the china NMPA for the treatment of polyarticular juvenile idiopathic arthritis (pJIA). This is the fourth approved indication of SULINNO® in China.

Lead Product(s): Adalimumab

Therapeutic Area: Immunology Product Name: Sulinno

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 23, 2020

ASK
US

Upload
your Pipeline Activity

Innovent Biologics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Innovent Announces NMPA Granted Marketing Approval for SULINNO® (Adalimumab Injection) in China

Details:

SULINNO® (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis in China.

Lead Product(s): Adalimumab

Therapeutic Area: Immunology Product Name: Sulinno

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 03, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY